{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"}]}],"title":"overall survival (OS)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"}]}],"title":"progression-free survival (PFS)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"}]}],"title":"disease-free survival (DFS)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"}]}],"title":"event-free survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52"}]}],"title":"Relapse-free GVHD-free survival (GRFS)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Estimate incidence of overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), event-free survival, and relapse-free GVHD-free survival (GRFS) in patients receiving myeloablative, HLA-mismatched BMT for patients with high risk hematologic malignancies at 2 years. Incidence as a percentage.","groups":[{"description":"Patients with AML and MDS:\n\nDays -6 through -3: Busulfan q 5-6h IV q24h x 4 days\n\nDays -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV\n\nFor patients with ALL and lymphoblastic lymphoma:\n\nDays -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV\n\nDays -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days\n\nAll patients Day 0: Infuse unmanipulated bone marrow\n\nDay +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV\n\nDay +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day\n\nDay +30: Assess chimerism and disease status in bone marrow\n\nDay +35: Discontinue MMF\n\nDay +60: Assess chimerism and disease status in bone marrow\n\nDay 180: Discontinue tacrolimus\n\nCyclophosphamide: Chemotherapy administration\n\nTBI: Radiation Therapy\n\nBusulfan: Chemotherapy Administered\n\nUnmanipulated Bone Marrow: Bone Marrow Transplant\n\nTacrolimus: Immunosuppressive Drug Administered\n\nMycophenolate mofetil: Immunosuppressive Drug Administered","id":"OG000","title":"Haploidentical BMT With PTCy for Acute Leukemias and MDS"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Survival","type":"SECONDARY","unitOfMeasure":"percent"}